相关实验视频

Updated: Jun 23, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

通过氧二衍生物对c-Met激酶受体的潜在抑制的计算模拟研究:基于QSAR,分子对接,分子动力学

Li-Yuan Guo^1,2, Yu-Lu Yang^1,2, Jian-Bo Tong^1,2

¹College of Chemistry and Chemical Engineering, Shaanxi University of Science and Technology, Xi'an, 710021, China.

Chemistry & biodiversity

|June 26, 2024

概括

新的氧化衍生物被确定为癌症治疗的潜在c-Met抑制剂. 计算机辅助药物设计预测和验证具有高活性和稳定性对瘤相关蛋白质的化合物.

科学领域:

药用化学医学化学
计算机化药物发现技术
在瘤学瘤学.

背景情况:

介酶-表皮转变因子 (c-Met) 是一种受体氨酸激酶,与癌症进展有关.
开发新的c-Met抑制剂对于有效的癌症治疗至关重要.
针对c-Met活动提供了一个有前途的治疗策略.

研究的目的:

识别和设计新的氧化衍生物作为强大的c-Met抑制剂.
系统地研究这些衍生物与瘤相关蛋白之间的相互作用.
用计算方法预测和验证潜在的候选药物.

主要方法:

利用计算机辅助药物设计 (CADD),包括拓CoMFA和HQSAR用于定量结构-活性关系 (QSAR) 建模.
采用基于碎片的药物设计,通过组合结构碎片来产生新的化合物.
进行了分子对接,分子动力学和ADMET预测以验证.

主要成果:

开发了强大的拓CoMFA (q2=0.620,R2=0.837) 和HQSAR (q2=0.684,R2=0.877) 模型.
产生了20种具有预测活动优于模板分子的新型化合物.
确定了Y4,Y5和Y14化合物作为有前途的c-Met抑制剂,Y14显示出异常稳定性 (-165.18kJ/mol结合自由能量).

结论:

该研究通过综合CADD方法成功确定了潜在的c-Met抑制剂.
化合物Y14显示出作为抗癌疗法进一步开发的巨大潜力.
这些发现为设计未来c-Met抑制剂提供了有价值的框架.

关键词:

分子对接是分子对接.分子动力学模拟模型在QSAR中使用QSAR.在c-Met Met中使用.

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...